Management of Diabetes type 2 through Unani Formulation

Effect of Qurs Gulnar in Ziabetus (Type 2 DM) - A randomized controlled trial - DM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/07/009060

Enrollment

Registered

2017-07-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Ziabetus (Type 2 DM)

Interventions

Intervention1: Qurs Gulnar: 3 Qurs (tablt) BD for 45 days Control Intervention1: Diabeat Capsule: 2 Capsule BD for 45 days

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed cases of Daibetes mellitus with blood suger level 2. Fasting blood suger (up to 200mg/dl) >126mg/dl 3. Post prandial blood suger (up to 350mg/dl) >200mg/dl 4. Hba1c >6.5% 5. patients between 30-60 years of age of both sexes

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation 2. Complicated cases of Diabetes Mellitus such as Diabetic ketoacidosis, Retinopathy, Neuropathy, Coronary artery disease. Peripheral vascular disease, cerebrovascular disease, liver disease

Design outcomes

Primary

Measure	Time frame
Blood sugerTimepoint: 45 days	—

Secondary

Measure	Time frame
HbA1cTimepoint: 45days	—

Countries

India

Contacts

Public ContactMd Anzar Alam

Luqman Unani Medical College Hospital and Research Centre

khalideqbalgtch@gmail.com8431227105

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026